Analysts fell to the sidelines weighing in on Science 37 (SNCE – Research Report), Masimo (MASI – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Science 37 (SNCE)
Robert W. Baird analyst Eric Coldwell downgraded Science 37 to Hold today and set a price target of $5.75. The company’s shares closed last Monday at $5.67.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of
Science 37 has an analyst consensus of Strong Buy, with a price target consensus of $21.92.
See the top stocks recommended by analysts >>
Masimo (MASI)
Masimo received a Hold rating and a $121.00 price target from Jefferies analyst Matthew Taylor yesterday. The company’s shares closed last Monday at $130.25.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Masimo with a $111.60 average price target, implying a -12.4% downside from current levels. In a report issued on January 15, Wells Fargo also maintained a Hold rating on the stock with a $117.00 price target.
Idexx Laboratories (IDXX)
In a report released today, David Westenberg from Piper Sandler downgraded Idexx Laboratories to Hold, with a price target of $525.00. The company’s shares closed last Monday at $532.06.
According to TipRanks.com, Westenberg is a 3-star analyst with an average return of
Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $588.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNCE:
- Science 37 Announces Upcoming Merger Agreement Execution
- Science 37 Issues Regulation FD Informational Disclosure
- Science 37’s Agreement to Merge with eMed Entity
- Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
- Science 37 Receives Top Honors in Everest PEAK Matrix®
